Osteoporosis Treatment Market By Drugs Type (Selective Estrogen Receptor Modulators (SERMs), Rank Ligand (RANKL) Inhibitor, Calcitonin, Hormone Therapy, Parathyroid Hormone-Related Protein (PTHrP) Analog, and Bisphosphonates (Risedronate, Alendronate, Ibandronate, Zoledronic Acid, And Others)), By Route of Administration (Injectable, Oral, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospitals Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Brand: Prophecy Market Insights
SKU: Pharmaceutical
Price: 5300 USD
Availability: InStock
Rating: 3.71 (12 reviews)

Report Code: PMI10818 | Publish Date: March 2024 | No. of Pages: 171

Global Osteoporosis Treatment Market By Overview

Osteoporosis is a condition in which body loses too much bone and there is an increase in bone weakness. The individual suffering from osteoporosis is more exposed to bone fractures. Hence, a proper treatment is required to cure and avoid the chances of complications. Osteoporosis is a bone disease which involves a continuing weakening of the bones. Osteoporosis reduces the bone density and often leads to fracture in hip, spine, and wrist etc. Some factors may lead to osteoporosis includes low intake of calcium, vitamin D, and magnesium, genetic factors, excessive alcohol intake, physical inactivity, and eating disorders. Osteoporosis can be treated with various medications such as selective estrogen receptor modulators (SERMs) etc., diet and nutrition, exercise, and lifestyle changes. The Osteoporosis Treatment Market accounted for US$ 11.60 billion in 2020 and is estimated to be US$ 17.68 billion by 2030 and is anticipated to register a CAGR of 4.3%.

Global Osteoporosis Treatment Market By Dynamics

Launches of new drugs

Launches of new drug in market by key players are expected to create good atmosphere for the growth of osteoporosis market growth. For instance, Teva Pharmaceutical Industries Ltd., a key player in market launched generic version of Actonel (risedronate sodium) Tablets, 5 mg, 30 mg, and 35 mg in U.S. The new launched tablet is indicated for the treatment of osteoporosis in women after menopause.

High rates of Osteoporosis

High rates of osteoporosis are expected to increases demand for osteoporosis treatment drugs and are expected to fuel market growth. For instance, as per the International Osteoporosis Foundation, around 75 million people in Europe, U.S. and Japan are suffering from osteoporosis. Furthermore, the increasing prevalence of ageing population is also expected to increase demand for osteoporosis drugs as old people are more prone to osteoporosis disease. Increasing rate and incidence of osteoporosis is expected to be a major factor which will boost the demand for its treatment products in market in upcoming time period. For instance, as per the International Osteoporosis Foundation, around 75 million people in Europe, U.S. and Japanare suffering from osteoporosis.

Geriatric population is more exposed to osteoporosis diseases. Hence, the increasing rates of geriatric population are also expected to upsurge the demand for osteoporosis treatment products in upcoming period of time.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Osteoporosis Treatment Market By Segmentation

The osteoporosis treatment market has been segmented on the basis of product type, route of administration, distribution channel, and region.

The drugs type segment includes selective estrogen receptor modulators (SERMs), rank ligand (RANKL) inhibitor, calcitonin, hormone therapy, parathyroid hormone-related protein (PTHrP) analog, and bisphosphonates (risedronate, alendronate, ibandronate, zoledronic acid, and others.

On the basis of route of administration, the osteoporosis treatment market has been segmented into injectable, oral and others.

On the basis of distribution channel, the osteoporosis treatment market has been segmented in retail pharmacies, online pharmacies, and hospitals pharmacies.

Regional Insights:

For detailed understanding of market dynamics, on the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions. For detailed understanding of market dynamics, the Osteoporosis Treatment Market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute	Details
Base year for estimation	2020
Forecast period	2020 – 2030
Market representation	Revenue in USD Million & CAGR from 2020 – 2030
Market Segmentation	By Drug Type- Selective Estrogen Receptor Modulators (Serms), Rank Ligand (RANKL) Inhibitor, Calcitonin, Hormone Therapy, Parathyroid Hormone-Related Protein (Pthrp) Analog, And Bisphosphonates (Risedronate, Alendronate, Ibandronate, Zoledronic Acid, And Others. By Route of Administration- Injectables, Orals and Others By Distribution Channel- Retail Pharmacies, Online Pharmacies, And Hospitals Pharmacies
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Osteoporosis Treatment Market, By Drugs Type:

Selective Estrogen Receptor Modulators (SERMs)
- Bisphosphonates
  - Alendronate
  - Risedronate
  - Ibandronate
  - Zoledronic Acid
  - Others
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Hormone Therapy
- Calcitonin
- Rank Ligand (RANKL) Inhibitor

Osteoporosis Treatment Market, By Route of Administration:

Injectable
- Others
- Oral

Osteoporosis Treatment Market, By Distribution Channel:

Retail Pharmacy
- Hospitals Pharmacy
- Online Pharmacy

Osteoporosis Treatment Market, By Region:

North America
- North America Osteoporosis Treatment Market, By Drugs Type
- North America Osteoporosis Treatment Market, By Route of Administration
- North America Osteoporosis Treatment Market, By Distribution Channel
- North America Osteoporosis Treatment Market, By Country
  - U.S.
  - Canada

- - Europe
    - Europe Osteoporosis Treatment Market, By Drugs Type
    - Europe Osteoporosis Treatment Market, By Route of Administration
    - Europe Osteoporosis Treatment Market, By Distribution Channel
    - Europe Osteoporosis Treatment Market, By Country
      - Germany
      - UK
      - France
      - Russia
      - Italy
      - Switzerland
      - Sweden
      - Rest of Europe

- - Asia-Pacific
    - Asia-Pacific Osteoporosis Treatment Market, By Drugs Type
    - Asia Pacific Osteoporosis Treatment Market, By Route of Administration
    - Asia-Pacific Osteoporosis Treatment Market, By Distribution Channel
    - Asia-Pacific Osteoporosis Treatment Market, By Country
      - China
      - India
      - Australia & New Zealand
      - Japan
      - South Korea
      - Rest of Asia Pacific

- - Latin America
    - Latin America Osteoporosis Treatment Market, By Drugs Type
    - Latin America Osteoporosis Treatment Market, By Route of Administration
    - Latin America Osteoporosis Treatment Market, By Distribution Channel
    - Latin America Osteoporosis Treatment Market, By Country
      - Brazil
      - Mexico
      - Argentina and Chile
      - Rest of Latin America

- - Middle East
    - Middle East Osteoporosis Treatment Market, By Drugs Type
    - Middle East Osteoporosis Treatment Market, By Route of Administration
    - Middle East Osteoporosis Treatment Market, By Distribution Channel
    - Middle East Osteoporosis Treatment Market, By Country
      - GCC
      - Israel
      - Saudi Arabia
      - UAE
      - Rest of Middle East

- - Africa
    - Africa Osteoporosis Treatment Market, By Drugs Type
    - Africa Osteoporosis Treatment Market, By Route of Administration
    - Africa Osteoporosis Treatment Market, By Distribution Channel
    - Africa Osteoporosis Treatment Market, By Country
      - North Africa
      - Central Africa
      - South Africa

Global Osteoporosis Treatment Market By Key Players

Key players operating in the osteoporosis treatment market includes, GlaxoSmithKline Plc., Pfizer Inc., Daiichi Sankyo Company, Limited, Dr. Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co AG, Allergan plc., andAmgen Inc., and Teva Pharmaceutical Industries Ltd. Launches of new drug in market by key players are expected to create good atmosphere for the growth of osteoporosis market growth. For instance, Teva Pharmaceutical Industries Ltd., a key player in market launched generic version of Actonel (risedronate sodium) Tablets, 5 mg, 30 mg, and 35 mg in U.S. The new launched tablet is indicated for the treatment of osteoporosis in women after menopause. High rates of osteoporosis are expected to increases demand for osteoporosis treatment drugs and are expected to fuel market growth. For instance, as per the International Osteoporosis Foundation, around 75 million people in Europe, U.S. and Japan are suffering from osteoporosis. Furthermore, the increasing prevalence of ageing population is also expected to increase demand for osteoporosis drugs as old people are more prone to osteoporosis disease.

Global Osteoporosis Treatment Market By Company Profile

GlaxoSmithKline Plc.
- Business Strategies Overview
- Financial Performance
- Key Highlights
- Product Portfolio
- Company Overview
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Daiichi Sankyo Company Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Dr. Reddy's Laboratories
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Mylan Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Asahi Kasei Corporation
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- F.Hoffmann La Roche
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Merck & Co AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Allergan plc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Amgen Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview
- EffRx Pharmaceuticals SA
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Business Strategies Overview